Phase 1 a/b Study of C31510 Alone and in Combination with Fludarabine and Cytarabine in Patients with Relapsed or Refractory Leukemia, High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Trial Profile

Phase 1 a/b Study of C31510 Alone and in Combination with Fludarabine and Cytarabine in Patients with Relapsed or Refractory Leukemia, High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs Ubidecarenone (Primary) ; Cytarabine; Fludarabine
  • Indications Leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Berg Pharma
  • Most Recent Events

    • 21 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top